Temozolomide
Jump to navigation
Jump to search
Temozolomide is an oral alkylating agent used to treat glioma - especially glioblastoma.[1] The therapeutic effect is dependent on the O-6-methylguanine-DNA methyltransferase (MGMT) gene promotor methylation.
See also
References
- ↑ Stupp, R.; Hegi, ME.; Mason, WP.; van den Bent, MJ.; Taphoorn, MJ.; Janzer, RC.; Ludwin, SK.; Allgeier, A. et al. (May 2009). "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.". Lancet Oncol 10 (5): 459-66. doi:10.1016/S1470-2045(09)70025-7. PMID 19269895.